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Host defense peptides (HDP) are naturally occurring effector molecules of the innate immune system, which might be an alternative to currently used antibiotics. The objective of this study was to investigate the efficiency of transient cutaneous adenoviral transfection with human cathelicidin hCAP-18/LL-37 in infected burn wounds. Specific transgene expression was analyzed in vitro on mRNA and protein level using realtime PCR and Western-blot. Male Sprague-Dawley rats (n ¼ 40) received a second degree scald burn on both flanks (5% BSA), which were inoculated with 10 8 colony-forming units (CFU) Pseudomonas aeruginosa. Two days later, rats were randomized into the following groups: (1) adenoviral delivery of LL-37 (Ad5-hCAP-18, n ¼ 10), (2) synthetic host defense peptide LL-37 (1 mg; n ¼ 10), (3) carrier control (PBS, n ¼ 10) and (4) empty-virus control (Ad5-LacZ, n ¼ 10). Agents were injected intradermally and subcutaneously into both flanks. After either 2 or 7 days, skin samples were harvested and homogenized. CFU per gram tissue were determined. The hCAP-18/LL-37 expression was confirmed by real-time PCR and localized using in situ hybridization. In vitro transfection of cutaneous cells delivered a specific response on mRNA production. Western blot analysis revealed protein expression of hCAP-18/LL-37 in conditioned medium and cell pellet. The host defense peptide LL-37 was detectable after cleavage of the inactive pro-form hCAP-18/LL-37 with human elastase. Ad5-hCAP-18 showed a significant bacterial inhibition of approximately 10 000 fold compared to the control group (Po0.001) and 1000-fold (Po0.001) compared to the synthetic HDP LL-37 7 post-transfection. No inhibition was observed for the carrier or empty-virus control. Real-time PCR and in situ hybridization confirmed expression of hCAP-18/LL-37. In conclusion,
Introduction
Once burned patients have vanquished the acute, lifethreatening 48 h with inhalation trauma, protein loss and volume deficiency shock, they have to face another creeping and increasing problem -wound infection with multidrug resistant bacteria. 1, 2 Despite advances in the management of burned patients and development of powerful antibiotics, burn wound infection still remains a serious problem with high rates of morbidity and mortality. 3 Like many other burn centers, we are encountering an increasing number of bacterial strains resistant to topical agents currently used for wound care, such as silver sulphadiazine, mafenide acetate and gentamicin sulphate, all of which were initially introduced in the 1960s. [4] [5] [6] Recent reports confirm that mortality continues to remain significantly higher in patients who have received inadequate antimicrobial therapy. 7 These persistent problems suggest that novel strategies need to be devised to more effectively prevent and treat burn wound infections. Considering the increased bacterial resistance to conventional antibiotics, present studies focus on investigating the biological activity of recently described naturally occurring host defense peptides (HDP). HDP have been identified from diverse organisms, including plants, insects, bacteria and vertebrates. 8 In mammals such peptides play an important role as the first line of defense in the innate immune system to fight invading microbes. Cathelicidins are one family of HDP characterized by conserved pro-peptide sequences, which have been identified in several mammalian species. 9 hCAP-18/LL-37 is the only antimicrobial peptide of the cathelicidin family identified in humans. It has been detected in leukocytes, such as neutrophils, monocytes, NK cells, gd cells, B cells and in the epithelial cells of the testis, the gastrointestinal and respiratory tracts and in inflamed skin as an inactive pro form. [10] [11] [12] Extracellular cleavage into a cathelinlike domain of 14.3 kDa and the 37-amino-acid-long C-terminus (LL-37) activates the pro peptide, which by its own has been identified in plasma, airway surface fluid and in wound secretions. 10, 11, 13 The peptide is induced by pro-inflammatory infectious stimuli and displays direct antimicrobial activity by interaction with the cell membranes of microorganisms.
14 Primarily understood as endogenous antibiotics, HDP obtain increasing importance as multifunctional mediators in the complex responses of innate immunity. It has been recently demonstrated that LL-37 performs a central role in linking the innate immune response and the inflammation with angiogenesis. 15 Owing to the loss of the mechanical barrier of the skin in burn injury and the locally reduced expression of HDP, patients are prone to bacterial colonization and wound infection. 14, [16] [17] [18] In addition, a deficiency of hCAP-18/LL-37 in the skin of patients with atopic dermatitis may predestine an increased risk for skin infections. 19 In order to augment the local immune response with administration of HDP, we compared the topical administration of the synthetic peptide LL-37 to adenoviral delivery of the transgene for hCAP-18/LL-37. Transient cutaneous transgene expression may be a potential alternative to the application of synthetically derived proteins in the treatment of acute wounds. Therefore, it is necessary to focus on a highly effective transient gene delivery system to promote local wound healing factors. Compared to other established gene transfer methods, including retroviruses and cationic lipids, adenovirus is independent of cell division state. 20 Furthermore, it has been previously demonstrated that adenoviruses transduced cutaneous cells, such as sebaceous glands, smooth muscle cells, adipocytes, fibroblasts and keratinocytes. 21 Normal skin can be efficiently transfected with viral and nonviral expression systems, [22] [23] [24] but little is known about the feasibility of adenoviral gene delivery in burn wounds.
The goal of this study is to assess the feasibility of transient cutaneous adenoviral gene delivery of the human host defense peptide hCAP-18/LL-37 in thermally injured and infected skin in comparison to single application of the synthetic peptide.
Materials and methods
Cell culture Keratinocytes. Freshly received human skin was washed in PBS (PAA Laboratories, H 15002, Linz, Austria). The skin was digested overnight with 0.2% dispase solution (4.7 U/ml, Gibco, 17105-041, Paisley, UK). The epidermis was gently peeled off, collected directly into Trypsin/EDTA-solution (0.05/0.02%, Gibco, 35400-027, Paisley, UK) and incubated at 371C for 5 min in a gently shaking water bath. The remaining dermis was used for the isolation of fibroblasts as described below. After Trypsin digestion stopped by adding FBS (HyClone, Logan, USA), the cell suspension was filtered through a 100 mm cell strainer (Becton Dickinson Heidelberg, Germany) and centrifuged at 400 g, 41C for 5 min. Cells were suspended into 5 ml complete keratinocyte medium containing 3:1 DMEM (Gibco, 21969-035, Paisley, UK) and counted by CASY s -1 (Schärfe-System, Reutlingen, Germany). Cells were seeded out with an amount of 75 000 cells/cm 2 into collagen Type I (Becton Dickinson Falcon, 354236, Heidelberg, Germany) precoated culture flasks.
Fibroblasts. The dermal tissue was cut into small pieces and weighed. A sterile Collagenase Type II solution (Gibco, 17101-015, Paisley, UK) was prepared in PBS with 3000 U/ml (3 ml Collagenase Type II solution/g tissue) and incubated at 371C overnight. After complete digestion of the tissue, the cell suspension was filtered through a 100 mm cell strainer. After centrifugation at 400 g for 10 min, the pellet was suspended in fibroblast culture medium containing DMEM (Gibco 21696-035, Paisley, UK), 10% FBS (Hyclone, Logan, USA) and 1% penicillin/streptomycin (50 U/50 mg/ml; ICN, Aurora, USA 
Virus purification
In this study, replication deficient human DE1 adenovirus serotype 5 with inserted CMV-promoter driven transgenes of human CAP18/LL-37 and Escherichia coli LacZ were used. The Vector Core, Gene Therapy Program, Division of Medical Genetics, Department of Medicine at the University of Pennsylvania, School of Medicine kindly provided the virus. The virus was propagated in 911 cells, 25 purified by two sequential CsCl 2 gradients and dialyzed against 20 mM Tris/HCl pH 8.0 containing 2 mM MgCl 2 . Titer was determined by Adeno-Xt rapid titer kit (Becton Dickinson Bioscience, Heidelberg, Germany). After addition of 10% glycerol, virus stocks were stored at À801C.
In vitro transfection
Cells were seeded one day before transfection with a density of 65 000 cells/cm 2 for primary human keratinocytes, 55 000 cells/cm 2 for fibroblasts, 100 000 cells/cm 2 for 911 and 75 000 cells/cm 2 for HaCaT. Used adenovirus was diluted into current medium without FBS (for protein sampling) or with 2% FBS for mRNA isolation. Cells were infected with an MOI (multiplicity of infection) of 1, 10 or 100. Plates were incubated at 371C, 5% CO 2 and gently rocked four times during the first hour. After 4 h, the medium was changed. The medium was further changed every second day. At 48 h after transfection, samples were taken. Protein. Culture medium was taken and cells were lysated. Solutions were centrifuged (4000 r.p.m., 5 min, Centrifuge 5417 R, Eppendorf, Hamburg, Germany) and the resulting supernatant was incubated with MacroPrep (75:1, BioRad, Hercules, USA) dispersion (41C, overnight, shaking). Samples were centrifuged (1000 g, 5 min) and pellets were washed three times with 25 mM ammonium acetate (pH 6.8). Proteins were eluted from the resin using 10% acetic acid and buffered with 1 M Tris/Hcl (pH 7.4).
Protease cleavage
Derived protein samples were incubated for 1 h at 371C using 2 mU/ng peptide of neutrophil-purified human elastase (Calbiochem, Bad Soden, Germany). The samples were subsequently boiled in Laemmli sample buffer and run on a sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting.
Western blotting
Samples were added to a 16.5% discontinuous SDS-PAGE and then electro-blotted on to nitrocellulose membrane (Amersham Bioscience, Freiburg, Germany). After blocking with 5% skim milk in phosphate-buffered saline for 1 h, the filters were incubated overnight with rabbit polyclonal anti hCAP-18 antibody (1:10 000; kindly provided by R Gallo, UCLA, USA). The membranes were then incubated with horseradish peroxidase-conjugated anti-rabbit mice IgG (Promega, Mannheim, Germany) and exposed on X-ray radiograph (Hyperfilm, Amersham Pharmacia Biotech, Buckinghamshire, UK) after development using enhanced chemiluminescence (Amersham Pharmacia Biotech, Buckinghamshire, UK).
RNA isolation
Isolation of total RNA was done using the RNeasy Mini Kit (Qiagen, Hilden, Germany), following the manufacturer's instructions for animal cells including DNAdigestion (RNase-free DNase Set, Qiagen, Hilden, Germany). RNA was eluted in a final volume of 50 ml RNase-free H 2 O. The concentration of RNA was determined using the Eppendorf Biophotometer (Eppendorf, Hamburg, Germany).
A punch biopsy (4 mm, Stiefel, Offenbach, Germany) was taken and weighed in order not to exceed 30 mg. Tissue was stored at À801C in RNAlater (Qiagen, Hilden, Germany) until further processing. Isolation of total RNA was done using the RNeasy Protect Mini Kit, following the manufacturer's instructions for isolation of total RNA from skin including DNA-digestion (RNasefree DNase Set, Qiagen, Hilden, Germany). RNA was eluted in a final volume of 30 ml RNase-free H 2 O. The concentration of RNA was determined using the Eppendorf Biophotometer (Eppendorf, Hamburg, Germany).
Reverse transcription
For reverse transcription, 1 mg of total RNA was used. Total RNA was transcribed into cDNA using the SuperScriptt First Strand Synthesis System for RT-PCR (Invitrogen, Karlsruhe, Germany), following the manufacturer's instructions for first-strand synthesis using random primers.
Real-time PCR
Relative quantification of mRNA was performed in a two-step real-time RT-PCR procedure using the fluorescent dye SYBR Green I (Light Cycler FastStart DNA Master SYBR Green I, Roche, Mannheim, Germany) and a Light Cycler (Roche, Mannheim, Germany). The produced cDNA from RT-reaction was amplified by real-time PCR using specific primers for hCAP-18/ LL-37 (sense: 5 0 -ATCATTGCCCAGGTCCTCAG-3 0 , antisense: 5 0 -GTCCCCATACACCGCTTCAC-3 0 , 251 bp) and, as housekeeping gene, primers for 18S rRNA (sense:
0 ). These primer pairs were validated to generate a single PCR-product. A standard curve for hCAP-18/LL-37 was incorporated in each PCR analysis. Standard curve and samples were analyzed in triplicate. The cycling conditions for detection of 18S rRNA were similar. mRNA concentrations for hCAP-18/LL-37 were normalized for 18S rRNA in each sample.
In situ hybridization
Skin tissue samples were formalin-fixed and 4 mm paraffin embedded sections were prepared. Digoxigenin labeled sense and antisense probes were established using the manufacturers guidelines (Roche, Mannheim, Germany). Slides were dewaxed and washed with depcwater. Sections were fixated in 4% paraformaldehyde, washed several times with PBS, dehydrated through ethanol and dried. After 20 min of incubation with 0.2 N HCl, a pronase digestion was performed for 10 min. Sections were rinsed with PBS, incubated again in 4% paraformaldehyde (20 min), rinsed in PBS and incubated in 0.1 M triethanolamin (10 min), rinsed again in PBS and dehydrated through ethanol. After drying, prehybridization was performed for 2 h at 421C in 50% formamide, 1 mM DTT, 300 mM NaCl, 10 mM Tris/HCl (pH 7.5), 10 mM Na-phosphate buffer (pH 6.8), 0.5 mM EDTA, 0.1 Â Denhardt's solution, yeast t-RNA, 12.5% dextransulphate and salmon sperm. Sections were hybridized over night at 421C with digoxigenin-labeled probes in pre-hybridization solution. For immunological detection of the probe, the sections were incubated for 2 h at 371C with a fluorescent-labeled anti-digoxigenin antibody (Fab-fragment; Roche, Mannheim, Germany). Sections were rinsed with PBS several times, dehydrated through ethanol and counterstained by propidiumjodid.
Bacterial culture
Bacteria were grown overnight in standard Luria Bertani (LB) Broth medium (Roth, Karlsruhe, Germany). The resulting stationary-phase cultures were transfused into fresh LB medium and incubated for 2.5 h at 371C to reach the mid-logarithmic phase. The subculture was centrifuged (10 min, 41C, 880 g, Megafuge R 1.0, Haereus, Hanau, Germany) and the resulting bacterial pellet was /ml.
Animal model
The research protocol described below conformed to all regulations related to animal use and other federal statutes. It was conducted in compliance with the principles in the 'Guide for the Care and Use of Laboratory Animals' from German Animal Welfare Act. After arrival, animals were handled and housed for 2 weeks at the animal facility of the University Clinic of Plastic Surgery BG Hospitals Bergmannsheil, RuhrUniversity Bochum, before starting the experiment. Animals were kept under stable conditions, temperature of 221C, 12 h light cycle and 65% humidified atmosphere.
The infected rat burn model was used as previously described. 26 In this experiment, 40 adult male, pathogenfree Sprague-Dawley rats weighing 220-260 g were used. At 24 h after depilation, the rats were anesthetized. After immersing defined skin areas for 20 s in 601C hot water, both burned areas were dried, marked and thoroughly disinfected. A bacterial solution of 250 ml was added topically, containing a definite number of CFU (1 Â At 2 days postinfection, the infected burned areas were subdivided into definite squares (1.5 Â 1.5 cm). Treatment was applied to these areas by one intradermal injection of 150 ml of the corresponding solution and another subcutaneous application of 150 ml. The following solutions were applied: Ad5-hCAP-18/ LL-37 (2 Â 10 8 IU/300 ml), pure synthetic peptide LL-37 (100 mg; 300 ml) as positive control and phosphatebuffered saline (PBS; 300 ml) as negative control. Prof Dr Henklein (Charité Berlin, Germany) produced the purified synthetic peptide LL-37. An additional empty virus control group (Ad5-CMV-lacZ) was prepared for control at day 7. Immediately after application, the wounded areas were bandaged occlusively.
After either 48 h or 7 days, a lethal dose of 1 ml Narcoren s (Pentobarbital-Sodium, Athen, USA) was applied intraperitoneally. The infected wound tissues were harvested aseptically, weighed and homogenized in PBS with a rotor stator homogenizer Polytron s PT3100 (Kinematika, Luzern, Swiss). Serial dilutions (1:1000, 1:10 000, 1:100 000 and 1:1 000 000) were made and 10 ml were transferred in triplicate to Pseudomonas isolation agar (Becton Dickinson, Heidelberg, Germany) and on Mueller Hinton agar with 5% sheep blood (Becton Dickinson, Heidelberg, Germany). The plates were incubated for 18 h at 371C. Colonies were counted and multiplied with the corresponding dilution factor. Results were evaluated by calculating the number of CFU/g of tissue.
Statistical analysis
Data were analyzed by analysis of variance (ANOVA) and independent sample t-test when the data had a normal distribution (SPSS, Chicago, USA). Results were considered to be significant at Po0.05. All values were marked as mean7s.e.m.
Results

In vitro transfection
Adenoviral transfection efficacy for hCAP-18/LL-37 was dose and cell dependent (Figure 1 ). Highest transgene expression was seen in the helper cell line 911 (MOI 1: 14 pg/ng rRNA; MOI 10: 72.75 pg/ng rRNA; Figure 1b) followed by primary human keratinocytes (MOI 1: 4.8 pg/ng rRNA; MOI 10: 13 pg/ng rRNA; Figure 1c) , primary human fibroblasts (MOI 1: 0.012 pg/ng rRNA; MOI 10: 0.128 pg/ng rRNA; Figure 1a ) and HaCaT keratinocyte cell line (MOI 1: 0.0028 pg/ng rRNA; MOI 10: 0.033 pg/ng rRNA; Figure 1d ). Within all cases, significant (Po0.01) differences were seen between MOI of 1 and 10. Constitutive expression for hCAP-18/LL-37 was observed for primary human fibroblasts (0.06 fg/ng rRNA) and primary human keratinocytes (3.6 pg/ng rRNA), whereas no constitutive expression was detectable for the helper cell line 911 and HaCaT keratinocyte cell line.
Transgene expression
Western-blot analysis demonstrated specific expression of the full-length hCAP-18/LL-37 pro-peptide in the helper cell line 911 after adenoviral transfection with hCAP-18/LL-37 transgene (Figure 2 , Àelastase), while no expression was seen in the carrier control (Figure 2 , Ad5-EGFP). Beneath the cell pellet, a high level of hCAP-18 was also detectable in conditioned medium. Without human elastase, no cleavage was seen (Figure 2, 371C) . Digestion of purified hCAP-18 from conditioned medium (supernatant, S) and cell pellet (P) of the helper cell line 911 with human elastase (2 mU/ng peptide) resulted in smaller fragments (Figure 2, +elastase) . The resulting fragments, as well as the pro-peptide, were running in excess of their expected molecular weight. A double band of unclear generation was seen for hCAP-18 detection within cell pellet preparation but not within conditioned medium. Neither hCAP-18 nor fragments were detectable in untreated 911 cells (Figure 2 , Ad5-EGFP). Pure synthetically derived LL-37 (1 ng), which was used as positive control (+), demonstrated a second band, running at the same molecular weight as the small fragment of the elastase cleaved hCAP-18 ( Figure 2 , +elastase, P).
Animal model
The burned skin first showed notable paleness immediately after scald injury, followed by a reddish pink coloration after a few minutes. Neither at the day of treatment nor at day 2 post-treatment were differences macroscopically visible between groups. All wounds were wet and purulent. At day 7 post-treatment, dry eschar was seen on wounds treated with Ad5-hCAP-18, whereas the wounds of all other groups were mucous between the peripheral eschar and the wound bed. The results of the in vivo study demonstrated that the peptide 12 CFU/g tissue for the the carrier control and the synthetic peptide (LL-37) group also showed growth up to 1.9 Â 10 11 CFU/g tissue ( Figure 3) . The efficacy of an adenovirus type 5 (Ad5) containing the CMV-promoter driven transgene hCAP-18/LL-37 was displayed and compared to carrier control group and synthetic peptide group at 2 and 7 days post-transfection.
To exclude a responsible effect of the viral construct on the inhibition of the bacterial growth, an empty virus control group was performed for the 7-day time point. Therefore, a reporter gene construct (Ad5-LacZ), containing the same backbone as Ad5-hCAP-18 except for the transgene, was chosen as an empty-virus control. There was no evidence that the Ad5 on its own is able to inhibit bacterial growth, as there was no difference observed between the empty virus control and the carrier (PBS) control (data not shown).
To confirm the results of the CFU counts per time point, additional skin punch biopsies were taken from nine rats (three out of each group) and total mRNA was extracted. To compare relative transcript amounts, 18S-RNA was amplified as a housekeeping gene. Linearized plasmid containing the same genetic information for hCAP-18 was used as positive control. As demonstrated in Figure 4 , a specific transgene expression for hCAP-18/ LL-37 could only be detected in the treatment, but not in the carrier control group after 2 and 7 days. In order to confirm the RT-PCR data with a quantitative analysis, we performed real-time PCR with SYBR green I dye. A quantitative assessment of final values obtained by RT-PCR can be only semi-quantitative because limiting reagents, small differences in reaction components or cycling parameters could influence the results. Real-time PCR data are obtained during the exponential phase of PCR amplification, thus providing a more reliable Western blot analysis was performed for hCAP-18 in supernatant and pellet of Ad5-hCAP-18 transduced 911 cells. Samples were generated 48 h post-transfection and analyzed with or without elastase (2 mU/ng peptide, 1 h, 371C) cleavage; Marker (M); Ad5-hCAP-18 from supernatant (S) cell pellet (P) without cleavage (Àelastase); Ad5-hCAP-18 from supernatant (S) and cell pellet (P) after cleavage (+elastase); positive control, 1 ng of synthetically derived LL-37 as positive (+) and Ad5-hCAP-18 pellet without elastase incubated for 1 h at 371C (371C); Ad5-EGFP supernatant (S) and cell pellet (P) from Ad5-EGFP transfected cells (Ad5-EGFP).
Transient cutaneous adenoviral gene therapy with human HDP hCAP-18/ LL-37 F Jacobsen et al quantitative analysis. The initial copy number of the gene of interest is based on the threshold cycle, which is inversely proportional to the log of the initial copy number in the template. SYBR green fluorescence binds nonspecifically to double-stranded DNA. Therefore, melting curve analysis was performed to confirm that the detection of fluorescence occurred above the melting temperature of possible primer-dimers (data not shown). Visualization on an agarose gel confirmed the purity of the amplified product and that no spurious products were presented (data not shown).
For the localization of transgene expressing cells, in situ hybriendization was prepared within formalin-fixedparaffin embedded tissue sections. Ad5-hCAP-18 transfected and untransfected burned areas were prepared and stained. The protocol was performed as expatiated in methods; two representative pictures, one of each group, are shown in Figure 5 .
A reduced epithelization was observed in burned skin treated with PBS only (Figure 5b) . Low background fluorescence, strong fluorescent erythrocytes and a few hair bulbs containing fluorescent keratin were visible. No specific green fluorescence was seen anywhere in the parts of the dermis or epidermis. Within the dermis and the rebuilt epidermis treated with Ad5-hCAP-18, some cells were positively stained for hCAP-18-mRNA (Figure 5a ).
Discussion
The importance of HDP in the immune response has been clearly demonstrated, as animals or human tissues defective in host defense peptide expression or proteolytic activation are more susceptible to specific infection. 27, 28 We observed that hCAP-18 was constitutively expressed in primary human keratinocytes and fibroblasts, whereas no specific mRNA was found in the used cell lines. This demonstrated an interesting difference between primary cells and corresponding cell lines that has not been described yet. Owing to the well accepted fact that keratinocytes play a fundamental part in the first line of defense, 29 the constitutive mRNA amount was drastically reduced in fibroblasts compared to keratinocytes (factor 10   5 ). The purified transgene product of 911 cells transduced by Ad5-hCAP-18 was cleavable using the human elastase into the catheline-like domain and the C-terminal antimicrobial peptide LL-37, whereas the Western-blot Transient cutaneous adenoviral gene therapy with human HDP hCAP-18/ LL-37 F Jacobsen et al demonstrated the same pattern as previously shown by Sorensen et al. 30 Nevertheless, a double band of hCAP-18/LL-37 could be detected solely in the cell pellet but not within the conditioned medium. Thus, we hypothesize that the upper band showed a cytosolic pro-form, which needed further progression until externalization. Data published by Cole et al 31 evaluated the fact that the antimicrobial activity of porcine cathelicidines was reduced if the neutrophile elastase was selectively inhibited. This study suggests that it is very likely that proteases, other than human proteinase 3 or elastase, which are the responsible enzymes for the cleavage of hCAP-18/LL-37 in humans, 30 are able to activate this HDP, as it was obviously activated in the rat's ichor.
As described in prior publications, the bioactive C-terminus of hCAP-18/LL-37 has been shown to exert antimicrobial activity toward both Gram-negative (minimal inhibitory concentration 12-25 mM) and Gram-positive bacteria (0.75-1.5 mM). 32 The final concentration of LL-37 synthetic peptide solution used in our study was about 1 mM per wound. With this, it was 50-fold the minimal inhibitory concentration against Gram-negative bacteria, which was determined in vitro. Still, LL-37 was not as effective as, for example, HBD 2 or 3 shown in many in vitro studies. However, LL-37 has a broader spectrum concerning the antimicrobial activity and is moreover able to induce neovascularization 15 and to demonstrate binding of bacterial endotoxin (LPS, minimal active concentration: 12.5 mg/ml) 14 or chemotactic activity for neutrophils, monocytes 33 and mast cells (effective concentration 1-10 mM). 32, 34 Finally, regarding the actual resistance problem of classic antibiotics and its rapid progress, it must be mentioned that there is only a very low tendency of developing resistance to HDP. 35, 36 Possible systemic side effects after systemic or local applications of LL-37 still remain a field for further investigations.
Many attempts have been made to make HDP therapeutically feasible for broad commercial use for a variety of implementations. 37 To date, studies attempt to find the optimum application form, dosage and frequency and are confronted with pharmacokinetic and toxic concerns of local or systemic application. They all have to face some common problems, eg the cost-and labor-intensive production of this HDP. 38 In consequence of the aggressive milieu of infected burns, it is inappropriate to use expensively purified synthetic or recombinant peptides. An alternative might be to rely on the host cellular machinery to manufacture locally the molecules of interest. 39 The fact that high-risk patients have to face complications due to frequent dressing changes, as generally applied in the current therapeutic principles in burn management, should also not be disregarded. 16, 40 By using a replication-deficient adenovirus serotype 5 for the transient induction of the HDP hCAP-18/LL-37 expression in an infected rat burn model, 41 we studied a basic concept to overcome some of these obstacles. In addition, skin is an interesting target for gene delivery because the treatment and monitoring is easy, but little is known about the efficiency of transient cutaneous adenoviral gene delivery in injured skin. 42 Bals et al were the only ones who previously described that adenoviral-mediated transient gene transfer allows the expression of hCAP-18/LL-37 to defeat bacterial infections. 43 Gene therapy was mostly understood as a permanent change or correction of inherited disorders. 44, 45 Owing to the fact that infections and wound healing in burns are known as a temporary process, a permanent treatment is rather ineffective and could induce new unexpected problems. Therefore, it is of great benefit that adenoviral vectors do not integrate their DNA within the host genome. They remain episomal and do not replicate; thus cell division leads to the eventual loss of the vectors from daughter cells. 46 The transient transfection is fast and effective, without leaving a scar once the vectors are lost. Even if several studies show sufficient expression from a few days to more than 3 weeks, the actual reason for the clearance of transfected cells remains unknown. 47 Our results demonstrated stable transgene expression within Ad5-hCAP-18-treated burned skin over the measurable time frame of 7 days. The transcription product was therefore localized within cells of the reticular layer and in keratinocytes of the epidermis. Overall, the immune response and pathophysiology after adenoviral gene delivery are not yet understood in detail. Acute immune response of the host after adenoviral treatment displays a serious risk after systemic administration. 48, 49 However, this risk might Figure 5 Transgene localization. Skin was harvested after 7 days post Transfection, formalin-fixed and paraffin embedded. In situ hybridization using digoxigenin labeled sense and antisense probes was performed and transcripts were detected by fluorescent labeled anti digoxigenin antibody (green). Nuclei were counterstained (red). Ad5-hCAP-18-treated burned skin showed decided green spots within the cytosol of keratinocytes and fibroblasts of the stratum papillare and epidermis (arrowheads, a). Within the carrier control treated cells no specific spots were seen (b). Note the autofluorescence of some erythrocytes and hairs.
Transient cutaneous adenoviral gene therapy with human HDP hCAP-18/ LL-37 F Jacobsen et al be minor after local application, especially if low intradermal or subcutaneous viral loads are used. 47 Within this study, we did show that a transient adenoviral gene delivery of hCAP-18/LL-37 with a single application is feasible and significantly more effective than a single dose of synthetically produced and purified HDP LL-37. Additional investigations about the long-term followup of the adenoviral gene delivery are needed as well as a survival study of animals receiving an infected burn.
Furthermore, it would be interesting to investigate other features of LL-37, eg its angiogenic and reepithelizating effects, 15 ,50 on infected burns using this model. Adenoviral-induced local LL-37 production could also support the immune system regarding the accessibility of the wound for supply or disposal, to neutralize LPS and to have chemotactic activity for neutrophils, monocytes and T-cells.
We conclude that transient cutaneous gene delivery has potential for delivery of HDP. More data are needed to better understand cutaneous adenoviral gene delivery and to optimize the vector system used in this study to circumvent safety risks. 51, 52 Further investigations are also needed to get a better understanding about the pathways HDPs act on during bacterial infection, the HDP with the highest potency for each infection and possible combinations of these HDPs to defeat infection and induce wound healing.
